Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.480 +0.020 (+1.37%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

August 21, 2023

From Enveric Biosciences

Via Business Wire

Cannabis Stock Gainers And Losers From August 16, 2023 ↗

August 16, 2023

Via Benzinga

Topics Cannabis

Marijuana Stock Movers For August 15, 2023 ↗

August 15, 2023

Via Benzinga

Topics Cannabis

Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024 ↗

August 14, 2023

Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show:

Via Benzinga

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results

August 14, 2023

From Enveric Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 08, 2023

Via Benzinga

Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers ↗

August 07, 2023

Via Benzinga

Cannabis Stock Gainers And Losers From August 11, 2023 ↗

August 11, 2023

Via Benzinga

Topics Cannabis

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 07, 2023

Via Benzinga

Cannabis Stock Movers For August 3, 2023 ↗

August 03, 2023

Via Benzinga

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

Marijuana Stock Movers For July 31, 2023 ↗

July 31, 2023

Via Benzinga

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

Cannabis Stock Gainers And Losers From July 28, 2023 ↗

July 28, 2023

Via Benzinga

Cannabis Stock Gainers And Losers From July 25, 2023 ↗

July 25, 2023

Via Benzinga

Cannabis Stock Gainers And Losers From July 26, 2023 ↗

July 26, 2023

Via Benzinga

Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More ↗

July 24, 2023

Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...

Via Benzinga

Enveric Unveils Positive Results From Preclinical Studies Supporting Metabolic Profile Of Its Psilocin Prodrug For Anxiety ↗

July 24, 2023

Enveric Biosciences (NASDAQ: ENVB) announced successful completion of preclinical absorption, distribution, metabolism, and excretion (ADME) and toxicology studies conforming to earlier positive...

Via Benzinga

Cannabis Stock Movers For July 24, 2023 ↗

July 24, 2023

Via Benzinga

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

July 24, 2023

From Enveric Biosciences

Via Business Wire

Enveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxiety ↗

July 17, 2023

Enveric Biosciences (NASDAQ: ENVB) announced positive results from pharmacokinetic animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable...

Via Benzinga

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

July 17, 2023

From Enveric Biosciences

Via Business Wire

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

Psychedelics Company Takes 'A Key Step' With New Formulation Of Its Psilocin Prodrug For Anxiety ↗

June 26, 2023

Enveric Biosciences (NASDAQ: ENVB) announced the development of an improved formulation of EB-373 designed to enhance the drug product’s scalability, stability, and delivery for ongoing preclinical...

Via Benzinga

Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

June 26, 2023

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

June 12, 2023

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)

June 07, 2023

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Stock Trading Higher On Notice Of Allowance For Patent Application For Its Carboxylated Psilocybin Derivatives ↗

June 05, 2023

Enveric Biosciences, Inc. (NASDAQ: ENVB) has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 series of...

Via Benzinga

Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates

June 05, 2023

From Enveric Biosciences, Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.